Targeted therapy shows efficacy in advanced PCa

“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.

Both the SOLAR-STAGE and SOLAR-RECUR trials are currently enrolling patients with prostate cancer in the US, with additional sites expected to open in Europe later this year.